Refractory headache: Historical perspective, need, and purposes for an operational definition

Headache

Volumn 48, Issue 6, 2008, Pages 770-777

  Schulman, Elliott A ^a   Brahin, Eric J ^b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Definition; Headache; History; Intractable; Migraine; Refractory

Indexed keywords

CLINICAL PRACTICE; HEADACHE; HEALTH CARE NEED; HEALTH SURVEY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; INTRACTABLE HEADACHE; INTRACTABLE MIGRAINE; MEDICAL RESEARCH; MEDICAL SOCIETY; MIGRAINE; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REFRACTORY HEADACHE; REFRACTORY MIGRAINE; REVIEW;

HEADACHE DISORDERS; HISTORY, 20TH CENTURY; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MIGRAINE DISORDERS; PAIN, INTRACTABLE; TERMINOLOGY AS TOPIC;

EID: 44849089674     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01135.x     Document Type: Review

References (44)

1. Lipton RB, Bigal ME, Diamond MD, Freitag F, Reed ML, Stewart MF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
2. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001 41 : 638 645.
3. Hu X, Markson L, Lipton R, Stewart W, Berger M. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999 159 : 813 818.
4. Headache Classification Subcommittee of the International Headache Society. The International classification of headache Disorders, 2nd edition. Cephalalgia. 2004 24 (Suppl. 1 8 152.
5. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000 62 : 509 525.
6. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001 358 : 1668 1675.
7. Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D Agonists) in the acute treatment of Migraine. Headache. 2004 44 : 414 425.
8. Lipton RB, Stewart WF, Sawyer MB, Edmeads JB. Clinical utility of an instrument assessing migraine disability: The migraine disability assessment (MIDAS) Questionnaire. Headache. 2001 41 : 854 861.
9. Lipton RB, Silberstein SD. The role of headache-related disability in migraine management. Implications for headache treatment guidelines. Neurology. 2001 56 : S35 S42.
10. Saper J, Lake AE, Lipton RB. Staging headache cases: Reconciling the complexity of a case with the required intensity of treatment. Headache. 2007 47 : 90 93.
11. Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. When headache treatment fails. Neurology. 2003 60 : 1064 1070.
12. Scher AI, Stewart WF, Lieberman J, et al. Prevalence of frequent headache in a population sample. Headache. 1998 38 : 497 506.
13. Castillo J, Munoz P, Guitera V, Pascual J. Kaplan award 1998: Epidemiology of chronic daily headache in the general population. Headache. 1999 39 : 190 196. CDH N, Silberstein S, Freitag F. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of headache. http://AAN.com.
14. Diener HC, Agnosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007 6 : 1054 1062.
15. Saper J. Approach to the intractable headache case: Identifying treatable barriers to improvement. Continuum December 2006, Volume 12, Issue 6.
16. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression (or for chronic daily headache) - clinical lessons. Headache. 2006 46 : S144 S146.
17. Tietjen G, Brandes J, Digre J, et al. History of childhood maltreatment is associated with comorbid depression in women with migraine. Neurology. 69 : 959 968.
18. Loder E, Biondi D. Disease modification in migraine. Headache. 2003 43 : 135 143.
19. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a â-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003 23 : 961 962.
20. Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007 115 : 81 83.
21. Hart A, Stegman M. ICD-9-CM, Ingenix 2007.
22. Smith R, Schwartz A. Diltiazem prophylaxis in refractory migraine. N Engl J Med. 1984 310 : 1327 1328.
23. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clincal practice and trials. Cephalalgia. 2006 26 : 1168 1170.
24. Schulman EA, Traumuta G. Refractory headache. Headache. 1993 33 : 273 286.
25. Clinicaltrials.gov. National Library of Medicine: Bethesda, MD. Available at: http://www.clinicaltrials.gov/ct2/search. Accessed January 8, 2008.
26. Leone M, May A, Franzini A, et al. Deep brain stimulation for intractable chronic cluster headache: Proposals for patient selection. Cephalalgia. 2004 24 : 934 937.
27. American Headache Society. Minutes of Refractory Headache Special Interest Section 2000-2005.
28. Schulman EA, Lake AE III, Peterlin BL, et al. Defining Refractory Migraine and Chronic Migraine: Proposed Criteria from the Refractory Headache Special Interest Section (RHSIS) of AHS: OR15. Headache. 2007 47 : 747.
29. Chayasirisobhon S. Use of a pine bark extract and antioxidant vitamin combination product as therapy for migraine in patients refractory to pharmacologic medication. Headache. 2006 46 : 788 793.
30. Valença MM. Intractable headache criteria. Cephalalgia. 2007 27 : 858 859. Author reply 859.
31. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002 42 : 515 518.
32. Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Naratriptan in the preventive treatment of refractory chronic migraine: A review of 27 cases. Headache. 2003 43 : 482 489.
33. Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997 37 : 377 382.
34. Mendes PM, Silberstein SD, Young WB, Rozen TD. Paolone MF. Intravenous propofol in the treatment of refractory headache. Headache. 2002 42 : 638 641.
35. Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the preventive treatment of refractory transformed migraine: A prospective pilot study. Headache. 2005 45 : 1400 1406.
36. Erdemoglu AK, Ozbakir S. Valproic acid in prophylaxis of refractory migraine. Acta Neurol Scand. 2000 102 : 354 358.
37. Donnet A, Valade D, Régis J. Gamma knife treatment for refractory cluster headache: Prospective open trial. J Neurol Neurosurg Psychiatry. 2005 76 : 218 221.
38. Donnet A, Tamura M, Valade D, Régis J. Trigeminal nerve radiosurgical treatment in intractable chronic cluster headache: Unexpected high toxicity. Neurosurgery. 2006 59 : 1252 1257. Discussion F, Behin B, Bigal ME, Lipton RB. Surgical treatment of patients with refractory migraine headaches and intranasal contact points. Cephalalgia. 2005 25 : 439 443.
39. Fisher M, Gosy EJ, Heary B, Shaw D. Dihydroergotamine nasal spray for relief of refractory headache: A retrospective chart review. Curr Med Res Opin. 2007 23 : 751 755.
40. Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM. Botulinum neurotoxin type A in the preventive treatment of refractory headache: A review of 100 consecutive cases. Headache. 2004 44 : 794 800.
41. Conway S, Delplanche C, Crowder J, Rothrock J. Botox therapy for refractory chronic migraine. Headache. 2005 45 : 355 357.
42. Magnoux E, Zlotnik G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache. 2004 44 : 249 255.
43. Stillman MJ. Testosterone replacement therapy for treatment refractory cluster headache. Headache. 2006 46 : 925 933.
44. Gallagher RM. Emergency treatment of intractable migraine. Headache. 1986 26 : 74 75.